Home>Topics>Stocks>Keryx Biopharmaceuticals

Keryx Biopharmaceuticals KERX

  1. All
  2. Commentary
  3. Headlines
    1. If Achillion's Hep C Nucleotide Isn't Best In Class, The Stock Is Worth Low Single Digits

      Headlines

      Tue, 16 Sep 2014

      By Adam Gefvert, CFA : Achillion Pharmaceuticals (NASDAQ: ACHN ) is a biotech company that focuses on developing treatments for Hepatitis C (HCV). Most of the company's value is riding on the success of its nucleotide, ACH-3422. Research suggests that if trials show that this nucleotide works only

    2. Keryx down again today

      Headlines

      Mon, 8 Sep 2014

      Keryx Biopharmaceuticals ( KERX -11% ) slumps again on a 5x surge in volume. Shares are off ~ 17% from the August 28 peak of $18.48. On Friday, the FDA

    3. Keryx Biopharmaceuticals' ( KERX ) CEO Ron Bentsur Discusses FDA approval of Ferric Citrate (Transcript)

      Headlines

      Mon, 8 Sep 2014

      By SA Transcripts : Keryx Biopharmaceuticals (NASDAQ: KERX ) Approval of Ferric Citrate Conference Call September 05, 2014 12:00 PM ET Executives Amy Sullivan - VP of Corporate Development

    4. Midday Gainers / Losers

      Headlines

      Mon, 8 Sep 2014

      28% . GIGA +24% . IHT +22% . RMGN +18% . GLRI +16% . MXC +14% . IPCI +13% . Top 10 Losers: VII -12% . ESYS -10% . DGLY -9% . KERX -9% . RVLT -9% . WRLD -9% . COUP -8% . TRMR -7% . CPE -8% . Post your comment!

    5. Keryx Falls Victim To A Self-Fulfilling Prophecy, Creates Opportunity

      Headlines

      Mon, 8 Sep 2014

      By Zvi Bar : On Friday, September 5, Keryx Biopharmaceuticals (NASDAQ: KERX ) received U.S. Food & Drug Administration ..... regarding the drug's safety warning, and that KERX shares will appreciate after investors realize the

    6. Premarket Gainers / Losers

      Headlines

      Mon, 8 Sep 2014

      Gainers: MGAM +29% . RADA +8% . HTZ +5% . Losers: HPTX -10% . WRLD -9% . KERX -8% . DGLY -6% . Post your comment!

    7. UPDATE 1-FDA approves Keryx's kidney drug with warnings, shares fall

      Headlines

      Fri, 5 Sep 2014

      Sept 5 (Reuters) - Keryx Biopharmaceuticals Inc won U.S. approval for its drug to lower phosphate levels in patients with chronic kidney disease (CKD), but the approval included an unexpected safety warning on the label.

    8. Weird request

      Commentary

      Fri, 5 Sep 2014

      My grandson in college tries to spot "opportunities" in the market. He had KERX spotted to rise today IF their new drug got approved. Well, the price moved DOWN from the open over 6% ... then the announcement

    9. Keryx to resume trading

      Headlines

      Fri, 5 Sep 2014

      According to NASDAQ , shares of Keryx Biopharmaceuticals ( KERX -6.2% ) will resume trading at 1:40 pm ET. Trading was halted earlier today pending the dissemination of the news of the FDA's approval of ferric citrate. Post your comment!

    10. FDA clears Keryx's ferric citrate, trading halted

      Headlines

      Fri, 5 Sep 2014

      The FDA approves Keryx Biopharmaceuticals ' ( KERX -6.2% ) ferric citrate (formerly Zerenex) for the control of serum phosphate levels in patients with chronic kidney disease

    « Prev123Next »
    Content Partners